Prevalence-Based Economic Evaluation

Mauskopf, Josephine

doi:10.1046/j.1524-4733.1998.140251.x

Cited by 61 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence-based approach measures the likely avoided costs if new cases are prevented (Larg & Moss, 2011). Such studies sum the estimated lifetime costs that are attributable to cases that occur during the defined incident period, following which future costs are appropriately adjusted to their present day value (i.e., discounting; Mauskopf, 1998;Torgerson & Raftery, 1999). The results derived from such studies can: (i) demonstrate how costs vary with disease duration (Larg & Moss, 2011); (ii) inform planning interventions targeted at specific stages (Fiscella, Lee, Davis, & Walt, 2009), and;(iii) can be used to inform the calculation of baseline costs for cost-effectiveness studies for interventions (Finkelsten & Corso, 2003;Goldstein, Reznik, Lapsley & Cass, 1986).…”

Section: Cost-of-illness Studiesmentioning

confidence: 99%

“…Such studies measure disease-attributable costs that occur concurrently with prevalent cases over a specific time period (usually one year; Larg & Moss, 2011). This approach is generally considered the most appropriate for assessing the total current economic burden of a health problem (WHO, 2009) as these studies usually include a cross-section of cases, thus capturing the costs at varying stages of disease (Mauskopf, 1998). However, this crosssection of individuals may also include cases that may not be amenable to intervention.…”

Section: Cost-of-illness Studiesmentioning

confidence: 99%

“…Discounting refers to the adjustment of costs to reflect future costs having less of a value than present day costs (Mauskopf, 1998). This analytical procedure should be conducted where costs extend over a one year period.…”

Section: Quality Checklist: Criteria and Scoringmentioning

confidence: 99%

See 2 more Smart Citations

The cost of work-related stress to society: A systematic review.

Hassard¹,

Teoh²,

Visockaite³

et al. 2018

Journal of Occupational Health Psychology

451

311

View full text Add to dashboard Cite

Objective. A global and systematic review of the available evidence examining the cost of work-related stress would yield important insights into the magnitude and nature of this social phenomenon. The objective of this systematic review was to collate, extract, review, and synthesize economic evaluations of the cost of work-related stress to society. Method.A research protocol was developed outlining the search strategy. Included cost-ofillness (COI) studies estimated the cost of work-related stress at a societal level, and were published in English, French or German. Searches were carried out in ingentaconnect, EBSCO, JSTOR, Science Direct, Web of Knowledge, Google and Google scholar. Included studies were assessed against ten COI quality assessment criteria.Results. Fifteen COI studies met the inclusion criteria and were reviewed. These originated from Australia, Canada, Denmark, France, Sweden, Switzerland, the United Kingdom, the United States, and the EU-15. At a national and pan-European level, the total estimated cost of work-related stress in 2014 was observed to be considerable and ranged substantially from US$221.13 million to $187 billion. Productivity related losses were observed to proportionally contribute the majority of the total cost of work-related stress (between 70 to 90%), with healthcare and medical costs constituting the remaining 10% to 30%. Conclusion.The evidence reviewed here suggests a sizeable financial burden imposed by work-related stress on society. The observed range of cost estimates across studies was understood to be attributable to variations in definitions of work-related stress; the number and type of costs estimated; and, in how production loss was estimated. It is postulated that the cost estimates identified by this review are likely conservative due to narrow definitions of work-related stress (WRS) and the exclusion of diverse range of cost components.2 Keywords: work-related stress; cost-of-illness study; society; burden of illness; systematic review 3 The Cost of Work-Related Stress to Society: A Systematic ReviewWork-related stress has become a major occupational risk factor in all industrialized countries, although comparatively less is known within many newly industrialized and developing countries (Kortum, Leka, & Cox, 2010). Much has been written about workrelated stress, and investigations conducted to examine and understand its associated human and organizational costs. However, much less attention has been paid to understanding the economic burden of this social and occupational phenomenon. Although small, this growing area of investigation attests to the substantial financial costs associated with psychosocial risks and work-related stress for organizations and national economies (Hoel, Sparks & Cooper, 2001;Sultan-Taïeb, Chastang, Mansouri & Niedhammer, 2013).For many in the field of Occupational Health Psychology (OHP) and beyond, such cost estimates are important (and often highly cited) sources of information. They are frequently used to illustr...

show abstract

Section: Cost-of-illness Studiesmentioning

confidence: 99%

Section: Cost-of-illness Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The cost of work-related stress to society: A systematic review.

Hassard¹,

Teoh²,

Visockaite³

et al. 2018

Journal of Occupational Health Psychology

451

311

View full text Add to dashboard Cite

show abstract

“…The confidence intervals for the cost per patient were determined by bootstrapping methods because of the small sample size and because cost data are not normally distributed [13,16,17]. All computations were done using the SAS/STAT® software, Version 9 of the SAS System for Windows.…”

Section: Methodsmentioning

confidence: 99%

Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis

Khellaf¹,

Moine²,

Poitrinal³

et al. 2010

Ann Hematol

View full text Add to dashboard Cite

Objectives: To report resource utilisation and annual cost for chronic immune thrombocytopenia (ITP) patients enrolled consecutively and followed for one year.Methods: A single-center, single-arm, retrospective, one-year observational cohort study of adult patients with chronic ITP from a French hospital. Healthcare resource utilisation and mean cost per patient (with 95% confidence intervals) were estimated for the whole group.Patients requiring at least one hospitalisation formed subgroup 1. Patients with the most severe category of disease formed subgroup 2 (defined as hospitalised patients with ≥1immunoglobulin (IVIg) infusion [usually reserved for those with bleeding score >8]).Results: Fifty-seven patients (42F/15M) with a mean age of 48 years (SD: 19) at ITP diagnosis were studied. Mean platelet count at diagnosis was 28±26x10 9 /L. Mean duration of ITP was 3.1 years (SD: 2); 8 patients had undergone splenectomy at baseline. Subgroup 1 included 27 patients who were hospitalised (full hospitalisation, n=23; and/or day hospitalisation, n=8). Of those, 12 patients received at least one IVIg infusion during hospitalisation (subgroup 2). Total mean cost per patient for the one-year study period was €7,293 (95% CI = 3,584) for the whole group, €15,334 (95% CI = 7,876-27,459) for subgroup 1, and €26,581 (95% CI = 12,578) for subgroup 2. IVIg accounted for 33% of costs for subgroup 1 and up to 43% of costs for patients with more severe disease (subgroup 2).Conclusions: Management of adults with chronic ITP is costly in France, especially for patients with severe disease. IVIg use was a major cost driver.

show abstract

“…Good practices for budget impact analysis (BIA) have been increasingly developed since the year 2000 [1,2]. As a financial approach, BIA is currently mandatory to support manufacturers' formulary submissions for national or provincial reimbursement in many countries (e.g.…”

Section: Introductionmentioning

confidence: 99%